By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.

Deadline approaching for type 2 remission programme competition

By Editor
2nd July 2019
Low carb, Low carb high protein diet Type 2 diabetes Type 2 diabetes remission Type 2 prevention

NHS organisations are being urged to get their entries into a competition to win access to an award-winning type 2 diabetes behaviour change platform.

Ascensia Diabetes Care launched the contest to give healthcare professionals the chance to offer free access for 200 people with type 2 diabetes to the award-winning Low Carb Program. The deadline for entries into Type 2 Diabetes Remission Accelerator, Powered by the Low Carb Program is July 10, 2019. To download the entry form, click here.

The online platform has been proven to reduce HbA1c, improve glycaemic control, lead to weight loss and reduce medications as well as having the potential to put the condition into remission.

NHS organisations such as NHS trusts, Clinical Commissioning Groups and NHS medical practices are being encouraged to enter the competition.

More than 200 individuals will be given access to the programme through their healthcare professional. Applications will be judged by a panel of NHS specialists and successful sites will need to demonstrate that they have an implementation plan for identifying, engaging and initiating patients onto the Low Carb Program within 8-10 weeks of notification of successful application. A commitment to evaluating the impact of the programme on behavioural change will also be required.

The platform, which is used by more than 400,000 people worldwide, has been developed by Diabetes Digital Media (DDM) in collaboration with Dr David Unwin, the RCGP National Champion for Collaborative Care and Support Planning in Obesity & Diabetes and RCGP Clinical Expert in diabetes as well as 20,000 people with diabetes.

The Low Carb Program has peer-reviewed outcomes, published in the Journal of Medical Internet Research (JIMR) Diabetes. Outcomes at year one include an average weight loss of 7.4kg; 39% of members completing the programme reduce their HbA1c below the type 2 diabetes threshold and one in four place their type 2 diabetes into remission, saving the NHS on average £853 per patient, per year, in reduced medication costs. The Low Carb Program is QISMET approved for NHS commissioning and included in the NHS App Library. It is also certified as a MHRA Grade 1 Medical Device and has a CE Mark in compliance with EU regulations.

The Low Carb Program facilitates sustainable weight loss and blood glucose control through structured education, resources and most importantly, personalised behaviour change support for people living with type 2 diabetes, pre-diabetes and obesity. In just under three months, most people with type 2 diabetes who complete the programme improve their blood glucose control whilst reducing or eliminating prescription medication and losing weight. After one year, data show that 26% of patients with type 2 diabetes are in remission.

On launching the competition, Ros Barker, Ascensia’s Country Head UK and Ireland, said: “Ascensia Diabetes Care is committed to ensuring the Low Carb Program is available across the UK and we hope that this competition will ignite the interest of primary care professionals across the country on the opportunity for type 2 diabetes remission. The Low Carb Program is supported by strong published evidence which includes the potential for members to reduce their medication and therefore save the NHS money.

“By entering this competition from Ascensia, you have the chance to trial the programme with your patients with type 2 diabetes for free and see the difference it can make to them. The Low Carb Program can revolutionise our approach to supporting people with type 2 diabetes, giving them the possibility of putting their condition into remission.”

The competition involves a simple application process. Interested GP practices and primary care groups should click here.

Comments (0)

Register an account or login to comment